These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 14963483)

  • 1. Outcomes in verteporfin photodynamic therapy for choroidal neovascularisation--'beyond the TAP study'.
    Barnes RM; Gee L; Taylor S; Briggs MC; Harding SP
    Eye (Lond); 2004 Aug; 18(8):809-13. PubMed ID: 14963483
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group.
    Arch Ophthalmol; 1999 Oct; 117(10):1329-45. PubMed ID: 10532441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2.
    Bressler NM;
    Arch Ophthalmol; 2001 Feb; 119(2):198-207. PubMed ID: 11176980
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization--verteporfin in photodynamic therapy report 2.
    Verteporfin In Photodynamic Therapy Study Group
    Am J Ophthalmol; 2001 May; 131(5):541-60. PubMed ID: 11336929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion composition's impact on vision outcomes-TAP report No. 3.
    Bressler NM; Arnold J; Benchaboune M; Blumenkranz MS; Fish GE; Gragoudas ES; Lewis H; Schmidt-Erfurth U; Slakter JS; Bressler SB; Manos K; Hao Y; Hayes L; Koester J; Reaves A; Strong HA;
    Arch Ophthalmol; 2002 Nov; 120(11):1443-54. PubMed ID: 12427056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Occult with no classic subfoveal choroidal neovascular lesions in age-related macular degeneration: clinically relevant natural history information in larger lesions with good vision from the Verteporfin in Photodynamic Therapy (VIP) Trial: VIP Report No. 4.
    Pieramici DJ; Bressler SB; Koester JM; Bressler NM
    Arch Ophthalmol; 2006 May; 124(5):660-4. PubMed ID: 16682587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Verteporfin photodynamic therapy for extrafoveal choroidal neovascularisation secondary to age-related macular degeneration.
    Voelker M; Gelisken F; Ziemssen F; Wachtlin J; Grisanti S
    Graefes Arch Clin Exp Ophthalmol; 2005 Dec; 243(12):1241-6. PubMed ID: 16010552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial.
    Azab M; Boyer DS; Bressler NM; Bressler SB; Cihelkova I; Hao Y; Immonen I; Lim JI; Menchini U; Naor J; Potter MJ; Reaves A; Rosenfeld PJ; Slakter JS; Soucek P; Strong HA; Wenkstern A; Su XY; Yang YC;
    Arch Ophthalmol; 2005 Apr; 123(4):448-57. PubMed ID: 15824216
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial--VIP report no. 1.
    Verteporfin in Photodynamic Therapy Study Group
    Ophthalmology; 2001 May; 108(5):841-52. PubMed ID: 11320011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Verteporfin photodynamic therapy of choroidal neovascularization in angioid streaks: one-year results of a prospective case series.
    Browning AC; Chung AK; Ghanchi F; Harding SP; Musadiq M; Talks SJ; Yang YC; Amoaku WM;
    Ophthalmology; 2005 Jul; 112(7):1227-31. PubMed ID: 15921757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1.
    Blinder KJ; Bradley S; Bressler NM; Bressler SB; Donati G; Hao Y; Ma C; Menchini U; Miller J; Potter MJ; Pournaras C; Reaves A; Rosenfeld PJ; Strong HA; Stur M; Su XY; Virgili G; ;
    Am J Ophthalmol; 2003 Sep; 136(3):407-18. PubMed ID: 12967792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Verteporfin : a review of its use in the management of subfoveal choroidal neovascularisation.
    Keam SJ; Scott LJ; Curran MP
    Drugs; 2003; 63(22):2521-54. PubMed ID: 14609361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Guidelines for using verteporfin (Visudyne) in photodynamic therapy for choroidal neovascularization due to age-related macular degeneration and other causes: update.
    Verteporfin Roundtable Participants
    Retina; 2005; 25(2):119-34. PubMed ID: 15689800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Photodynamic therapy with verteporfin following transpupillary thermotherapy for CNV evolving from an initially occult to a predominantly classic form, in patients with AMD.
    Hamon F; Goeminne P
    Semin Ophthalmol; 2001 Dec; 16(4):223-32. PubMed ID: 15513445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Verteporfin therapy in occult with no classic CNV due to AMD: results of the Photodynamic Therapy in Occult-Only Lesions study.
    Soubrane G; Harding SP; Wolf S; Weichselberger A
    Eye (Lond); 2009 Apr; 23(4):791-800. PubMed ID: 18583995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Photodynamic therapy in practice: a review of the results of the first 12 months experience with verteporfin at the Royal Victorian Eye and Ear Hospital.
    Essex RW; Qureshi SH; Cain MS; Harper CA; Guymer RH
    Clin Exp Ophthalmol; 2003 Dec; 31(6):476-81. PubMed ID: 14641153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiographic features after photodynamic therapy for choroidal neovascularisation in age related macular degeneration and pathological myopia.
    Parodi MB; Da Pozzo S; Ravalico G
    Br J Ophthalmol; 2003 Feb; 87(2):177-83. PubMed ID: 12543747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Japanese age-related macular degeneration trial: 1-year results of photodynamic therapy with verteporfin in Japanese patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration.
    Japanese Age-Related Macular Degeneration Tial (JAT) Study Group
    Am J Ophthalmol; 2003 Dec; 136(6):1049-61. PubMed ID: 14644215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Photodynamic therapy in age-related macular degeneration--results of one year observation].
    Wykrota H; Gierek-Łapińska A
    Klin Oczna; 2002; 104(3-4):239-43. PubMed ID: 12608309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Photodynamic therapy in the treatment of subfoveal choroidal neovascularisation.
    Harding S
    Eye (Lond); 2001 Jun; 15(Pt 3):407-12. PubMed ID: 11450766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.